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ZUMA-1 demonstrated a high rate of durable response and a manageable safety profile with
axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell
therapy, in patients with refractory large B-cell lymphoma. As previously reported,
prespecified clinical covariates for secondary end point analysis were not clearly predictive
of efficacy; these included Eastern Cooperative Oncology Group performance status (0 vs 1),
age, disease subtype, disease stage, and International Prognostic Index score. We
interrogated covariates included in the statistical analysis plan and an extensive panel of
biomarkers according to an expanded translational biomarker plan. Univariable and
multivariable analyses indicated that rapid CAR T-cell expansion commensurate with
pretreatment tumor burden (influenced by product T-cell fitness), the number of CD8 and
CCR71CD45RA1 T cells infused, and host systemic inflammation, were the most significant
determining factors for durable response. Key parameters differentially associated with
clinical efficacy and toxicities, with both theoretical and practical implications for optimizing
CAR T-cell therapy. This trial was registered at www.clinicaltrials.gov as #NCT02348216.
Introduction
Immunotherapy, especially genetically engineered T-cell therapy, is a revolutionary approach in the
fight against advanced-stage cancer.1-3 There are now 2 chimeric antigen receptor (CAR) products
approved to treat B-cell malignancies,4-9 1 of which is axicabtagene ciloleucel (axi-cel), an anti-CD19
CAR T-cell product approved for treatment of relapsed or refractory large B-cell lymphoma (LBCL) in the
United States and the European Union.4,10
Axi-cel demonstrated high objective and durable response rates in the multicenter ZUMA-1 study in adult
refractory LBCL,6 consistent with results from an earlier study that used the same CAR construct.11 Axi-cel
was associated with toxicities, most notably cytokine release syndrome (CRS) and neurologic events (NEs),
which are well described across this class of therapies.12-14 These toxicities are generally reversible and
manageable with supportive therapy, corticosteroids, and interleukin-6R (IL-6R) blockade.7,12,13
Despite high clinical efficacy, approximately 60% of patients do not respond to or relapse within 2 years
of treatment with axi-cel or other anti-CD19 CAR T-cell therapies.6,8 Mechanisms associated with
durable responses remain incompletely elucidated, and previous correlative analyses have largely
focused on toxicity and immune programs associated with CAR T-cell therapy.15-26 Data are limited on
Submitted 19 May 2020; accepted 12 August 2020; published online 9 October
2020. DOI 10.1182/bloodadvances.2020002394.
See supplemental Methods for Gilead’s data sharing policy.
The full-text version of this article contains a data supplement.
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mechanisms of treatment resistance, including target antigen loss
seen in a subset of responding patients. To date, most published
correlative data have been generated in leukemia patients, and
limited information has been obtained from large multicenter trials
irrespective of the tumor type.
Previous analyses of prespecified clinical covariates, including perfor-
mance status, age, disease subtype, disease stage, Interna-
tional Prognostic Index score, and cytogenetic status were not
clearly predictive of clinical efficacy in ZUMA-1.7,27 Therefore,
we initiated this study to analyze biomarker data from ZUMA-1
patients according to an expanded statistical analysis plan for
correlates of durable response and parameters differentially




Samples from patients in ZUMA-1 were analyzed. The study was
approved by the institutional review board at each study site and
was conducted in accordance with the Good Clinical Practice
guidelines of the International Conference on Harmonization.
Safety and efficacy results were previously reported.7 Durable
response referred to patients who were in ongoing response at
least 1 year after axi-cel infusion. Relapse referred to those patients who
achieved a complete or partial response and subsequently experienced
disease progression. Patients who achieved stable disease as best
response were considered nonresponders.
Quantification of CAR T cells
CAR T cells were quantified using TaqMan quantitative polymerase
chain reaction (qPCR; Thermo Fisher Scientific) as described28-31
and confirmed by droplet digital PCR (Bio-Rad Laboratories)
according to the manufacturer’s instructions. Unless otherwise
noted, results shown use the qPCR method (additional details
are provided in the supplemental Methods). A mathematical
derivation by which CAR cells were normalized to tumor burden
(TB) by dividing peak CAR T-cell levels by TB was used as an
indirect proxy for effector:target ratio.
Analysis of biomarkers and clinical covariates
Serum cytokines were analyzed by Simple Plex (Simpleprotein)
according to the manufacturer’s instructions or by using Luminex
(EMD Millipore) or V-Plex Multiplex assay panels (Meso Scale
Discovery) as previously described28 at baseline (before condition-
ing), on day 0 (axi-cel infusion day), or 1 day after axi-cel infusion, as
specified. T-cell phenotype was assessed by CCR7 and CD45RA
expression using multicolor flow cytometry with established protocols
and antibodies.28 Apheresis samples were presented as a percent-
age of live CD451 cells, and product samples were presented as
a percentage of live cells.
Lactate dehydrogenase (LDH) was quantified in each site’s
clinical laboratory. TB was estimated as the sum of product
diameters of up to 6 index lesions per Cheson 2007 criteria32
assessed by a local study site radiologist. Product T-cell fitness
was estimated functionally by the global doubling time (DT) of the
product cells in culture, the calculation of which is extensively
described in supplemental Methods.
Statistical analyses
Covariates and biomarkers from prespecified secondary end points
(see supplemental Translational Statistical Analysis Plan) were
interrogated for associations with safety, efficacy, and CAR T-cell
expansion. Specified covariates were assessed by quartile analysis (ie,
divided across 4 groupings of equal quantity or as equal as possible
with a given sample size) based on minimum to quartile 1 (Q1), Q1 to
median, median to Q3, and Q3 to maximum (supplemental Table 1).
For quartile analysis that is presented visually, the P value for logistic
regression analysis was provided.
For univariable analyses, Spearman’s rank-order correlation was
used to evaluate association between any 2 analytes. Logistic
regression was used to evaluate the relationship between covariate
and outcome. Kruskal-Wallis and Dunn’s tests were used when 3 or
more subgroups were involved in the comparison. P , .05 (not
adjusted for multiplicity) was considered a significant association.
Multivariable analyses were conducted with key covariates that
associated with efficacy, grade $3 toxicities, and/or peak CAR
T-cell levels after infusion. A set of biological control variables (ie,
disease stage, CAR transduction efficiency, total number of infused
T cells), which were not associated with these outcomes by
univariable analysis, were included in the model as internal controls.
Principal component analysis33 was used to generate hierarchical
clustering and demonstrate the relationships between covariates.
Directionality of association with given clinical outcomes has been
analyzed. Random forest analysis34 was used to identify covariates
most associated with durable response, grade $3 CRS, grade $3
NEs, and peak CAR T-cell expansion.
Results
High TB was associated with lower probability of
durable response, which could be overcome by
commensurate in vivo CAR T-cell expansion
Consistent with previous reports,6 higher peak expansion of CAR
T cells in the peripheral blood, specifically estimated as CAR cells
per unit of blood volume, was associated with both objective and
durable response (Figure 1A; supplemental Figure 1A-D; supple-
mental Table 2). Cumulative CAR T-cell levels over the first 28 days,
measured in blood by area under the curve, were also associated
with objective and durable responses (supplemental Figure 1E-H).
Levels of CAR T cells at 3 months and beyond were very low or
nonmeasurable7 and did not correlate with durable response
(Figure 1B).
We examined baseline TB and CAR T-cell numbers in the
peripheral blood after axi-cel infusion in association with the clinical
outcome to provide a mathematical derivation that would allow for
the assessment of effector:target ratio after CAR T-cell therapy in
lymphoma. In ZUMA-1 patients, low TB before CAR T-cell therapy
was a strong positive predictor of durable response (Figure 1C).
We hypothesized that higher TB as a result of increased CD19
antigen would associate with increased CAR T-cell numbers in the
peripheral blood. Although TB was not significantly associated with
CAR T-cell expansion, CAR T-cell levels trended positively with TB
in patients with durable response (supplemental Figure 1I). In
addition, there was a lower durable response rate at comparable
peak CAR T-cell levels in patients with higher TB compared with
patients who had lower TB (Figure 1D). Notably, durable responders
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had a higher peak CAR T-cell:TB ratio compared with nonresponders
(P 5 .005) or responders who subsequently relapsed within 1 year
after treatment (P5 .01; Figure 1E). Similar differences were observed
between peak CAR T-cell levels and TB ratio in complete responders
compared with partial responders (P 5 .001) or nonresponders
(P 5 .004; Figure 1F). Finally, there was a significant association
between overall peak CAR T cells and those normalized to TB
with both durable response rate and objective response rate
(Figure 1G-H; supplemental Figure 1J-K). These findings indicate that
early expansion commensurate with TB, rather than persistence of
functional circulating CAR T cells, is necessary for achieving durable
responses in refractory LBCL with an anti-CD19 CAR T-cell therapy
containing a CD28 costimulatory domain.
Proinflammatory and myeloid activation markers
correlated with impaired in vivo CAR T-cell expansion
and decreased rate of durable response
We hypothesized that inflammatory factors associated with high
TB may have an impact on CAR T-cell expansion and efficacy.
Pretreatment TB was generally associated with an enhanced
inflammatory state reflected by IL-6, ferritin, and IL-8, reminis-
cent of myeloid cell activation, as well as with LDH, indicative of
a tumor hypoxic microenvironment (supplemental Figure 2A). However,
tumor expression of myeloid- and inflammation-associated biomarkers
did not correlate to TB: IL-1A (R5 0.036; P5 .84), CD68 (R5 0.13;
P5 .45), IL-6 (R520.02; P5 .91), and CD14 (R5 0.04; P5 .81).
Pretreatment ferritin, LDH, and IL-6 were not associated directly
with in vivo CAR T-cell expansion; however, ferritin and LDH, but not
IL-6, were significantly (P , .01) but modestly (R , 20.3)
associated with lower CAR T-cell expansion normalized to pre-
treatment TB (peak CAR T-cell expansion/TB; Figure 2A-2C).
Pretreatment increases in LDH and IL-6, but not ferritin, were
associated with decreased durable response rates, whereas only
baseline IL-6 was associated with decreased objective response
(Figure 2D-F; supplemental Figure 2B-G). Similar associations
were seen when day 0 or day 1 levels of ferritin and IL-6 were
evaluated (supplemental Figures 3 and 4; supplemental Table 3). In
addition, there was a weak but significant association between
ferritin levels over the first 28 days and peak CAR T-cell levels
normalized to TB (R 5 20.2236; P 5 .0277). Significantly higher
levels of serum ferritin were observed at most time points after CAR
T-cell infusion in patients who relapsed or had no response
compared with those who had durable responses (supplemental
Figure 5). These data demonstrate that pretreatment TB and
Tumor burden (mm2)
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Figure 1. CAR T-cell expansion commensurate with baseline TB is associated with durable responses after axi-cel. Analysis of peak (A) and 3-month CAR T-cell
expansion (B) by response status. (C) The association of baseline tumor and probability of durable response was assessed by logistic regression. (D) Scatter plot of baseline
TB and peak CAR T-cell levels. (E-F) Analysis of peak CAR T-cell levels normalized to TB by response status. Logistic regression analysis evaluating the association of durable
response with peak CAR T-cell levels (G) and peak CAR T-cell levels (H) normalized to TB. P values were calculated using Kruskal-Wallis and Dunn’s tests. CR, complete
response; NR, no response; PR partial response.
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systemic inflammation were both negatively associated with the rate
of durable responses and that this effect was largely mediated by
decreased CAR T-cell expansion relative to the pretreatment TB.
Product T-cell fitness and dose of CD8 and CCR71
CD45RA
1
T cells were associated with response
We sought to determine key CAR T-cell product characteristics
associated with improved in vivo expansion and tumor responses. The
intrinsic ability of the entire product T-cell population, including CAR
T cells, to expand during nonspecific stimulation in vitro (ie, anti-CD3
antibodies in the presence of IL-2 during manufacturing) was
characterized by the culture DT. We evaluated product characteristics
for association with responses and found that low DT was the product
characteristic most significantly associated with objective response
compared with nonresponse (supplemental Table 4).
The median DT in responders vs nonresponders was 1.6 vs 2.1 days
(P5 .0067), and high DT was associated with a lower response rate
(Figure 3A; supplemental Figure 6A). DT itself was not associatedwith
durable response; however, there was a correlation between product
DT and expansion of CAR T cells in vivo after infusion (Figure 3B-C;
supplemental Figure 6A-B). This was mirrored by a similar negative
association between DT and peak CAR T cells normalized to TB, as
well as between DT and CAR T-cell area under the curve (Figure 3C-
D; supplemental Figure 6C).
Relative to other product characteristics, DT most strongly
associated with the frequency of T-cell differentiation subsets in
the final infusion bag. Specifically, DT positively associated with
the frequency of CCR7–CD45RA– T cells (R5 0.4341; P, .0001)
and negatively associated with the frequency of CCR71CD45RA1
T cells (R520.3837;P5 .0004; Figure 3E-H). DTwas not associated
with the CD4:CD8 ratio (Figure 3I). Together these results suggest that
intrinsic product T-cell fitness, as measured by the product DT, is
positively associated with a more differentiated product and
influences the ability of CAR T cells to expand in vivo to a sufficient
effector:target ratio that supports tumor eradication.
We hypothesized that manufacturing DT and product T-cell fitness in
general may be a direct result of the differentiation state of
patients’ T cells before enrollment. Apheresis T-cell phenotypes
were directly associated with the final product phenotype (Figure
4A-C). The phenotype of T cells in the apheresis product
associated with DT: greater proportions of CCR71CD45RA1 T cells
consistently associated negatively with product DT (Figure 4D-H;
supplemental Figure 7). We also found that TB and baseline ferritin
were significantly associated with the differentiation phenotype of
the final product (supplemental Figure 8). Altogether, these
findings connect product composition and clinical performance
to the pretreatment immune status of the patient.
To look at the association of product characteristics beyond DT
with durable response, we next assessed the number of infused
specialized T-cell subsets. The total number of infused CD8 T cells
was not statistically associated with response or peak CAR T-cell
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Figure 2. Baseline systemic inflammation is negatively associated with both CAR T-cell expansion relative to pretreatment TB and the rate of durable
responses. (A-C) Peak CAR T-cell expansion and peak CAR T-cell expansion normalized to TB were analyzed by quartile (Q) analyses of proinflammatory and myeloid
activation markers. (D-F) Logistic regression analysis evaluating the association of durable response with baseline proinflammatory and myeloid activation markers. Bar graphs
show medians per quartile, and Spearman’s correlation was used to calculate R and P values for all bar graphs.
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effector:target ratio, the number of infused CD8 T cells normalized to
TB was strongly associated with durable response and expansion of
CAR T cells (Figure 5D-F; supplemental Figure 9D-F), and patients in
the lowest quartile showed a durable response rate of 16% vs 58% in
the top quartile (supplemental Figure 9D). This suggests that higher
numbers of product CD8 T cells are needed to establish durable
responses in patients with higher TB. Indeed, in patients with high TB,
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Figure 3. Higher expansion rate of product T cells measured before infusion (doubling time) is associated with greater in vivo CAR T-cell levels and efficacy
and correlates with T-cell phenotype. Logistic regression analysis showing association of response (A) or durable response (B) with doubling time. Doubling time by peak
CAR T-cell expansion and peak CAR T-cell expansion normalized to TB (C) or by CAR area under the curve (AUC) (D) were analyzed by quartile analyses. Scatter plots show
association of doubling time with specified T-cell populations (E-H) and CD4:CD8 ratio (I). Bar graphs show medians per quartile, and Spearman’s correlation was used to
calculate R and P values for all bar graphs and scatter plots.
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showed a significantly higher number of infused CD8 T cells compared
with patients who responded and then relapsed (Figure 5G).
In addition, the number of infused CCR71CD45RA1 T cells was
associated with objective responses and peak CAR T-cell levels
(Figure 5H-J; supplemental Figure 9G-I), and a significant association
with durable response emerged when the number of infused CCR71
CD45RA1 T cells was normalized to TB (Figure 5K-M; supplemental
Figure 9J-L). In contrast, the number of infused cells in other subsets
was not associated with peak CAR T-cell levels (supplemental Figures
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Figure 4. The proportion of T cells with a more juvenile phenotype in the apheresis material directly associates with a lower product doubling time.
Association between T-cell phenotypes in apheresis material pre-gated on live CD451 cells and product phenotype (A-C) or product doubling time (D-H). Spearman’s correla-
tion was used to calculate R and P values.
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10A-D and 11A-D; supplemental Table 5). Notably the CD4:CD8 ratio
was not associated with peak CAR T-cell levels but was associated
with durable response (Figure 5N-P).
On the basis of these findings, we hypothesized that the CCR71
CD45RA1 subset of CD8 product T cells was most responsible for
achieving durable response. We performed more detailed subset
analyses in all patients with evaluable product samples (n 5 45
patients) and found that among CD8 T cells, the number of CCR71
CD45RA1 T cells was most significantly associated with durable
response (supplemental Table 6; supplemental Figure 12).
Product T-cell attributes, TB, host inflammatory
markers, and treatment-related type 1 T-cell activities
are differentially associated with efficacy
and toxicities
We next evaluated patient- and product-related markers for their
associations with severe toxicities to define actionable targets
and approaches to improve the risk-benefit profile of axi-cel.
Higher peak CAR T-cell expansion and baseline TB were
associated with grade$3 NEs but not grade$3 CRS (Figure 6;
supplemental Figures 13A and 14A). However, there was no
significant association between peak CAR T-cell expansion and
B-cell aplasia, a known on-target toxicity of anti-CD19 CAR
T-cell intervention (supplemental Figure 15). CAR T-cell levels
normalized to either pretreatment TB or body weight, DT, and
CD8 T cells or CCR71CD45RA1 CD8 T cells normalized to TB
were associated with efficacy but not with severe toxicities
(Figure 6B-C; supplemental Figures 13B-D and 14B-C). Increased
pretreatment or posttreatment proinflammatory, myeloid-related
cytokines, including IL-6, ferritin, and CCL2 as well as LDH, were
positively associated with grade $3 NEs or CRS (Figure 6D-G;
supplemental Figure 16).
We evaluated key features by the number of previous lines of
therapy. TB, markers of baseline inflammation, and DT increased
with increasing number of lines of therapy, but the proportion and
absolute numbers of CCR71CD45RA1 cells decreased (supplemental
Table 7). These findings support the observation that efficacy decreases
and toxicity increases with increasing number of lines of previous
therapy.35
We also systematically analyzed other routinely measured
product attributes for their differential association with efficacy
and toxicity. Notably, interferon-g (IFN-g) secretion of the final
product after coculture with CD19-expressing targets positively
associated with grade $3 NEs but not efficacy or grade $3
CRS in ZUMA-1 (Figure 6H; supplemental Figure 13F). There
was a weak, direct association between product coculture IFN-g
and the proportion of differentiated CCR7– T cells in the
infusion bag and product DT (supplemental Figure 17). Fur-
thermore, serum levels of IFN-g, CXCL10, and IL-15, measured
early after treatment also associated positively with grade $3
NEs but were not associated with durable response (supple-
mental Figure 18A-C). We also found that day 0 IL-15 serum
levels significantly associated with day 1 IFN-g serum levels
rather than product coculture IFN-g (supplemental Figure 18D).
Additional product release criteria were not associated with
efficacy or toxicity (supplemental Table 8). Altogether, these
findings point to product attributes and inflammatory biomarkers
that associated differentially with efficacy and toxicities after
treatment with axi-cel.
We performed a hierarchical clustering and random forest
multivariable analysis to further evaluate the univariable analysis
findings. Overall, random forest analysis confirmed the main
findings by univariable analysis and pointed to several param-
eters that associate differentially with response and toxicities,
namely baseline TB, IL-6, C-reactive protein, and LDH; day 0 IL-15;
and coculture interferon-g (Figure 7; supplemental Table 9). These
findings were supported by multivariable analysis that evaluated
covariates differentially associated with CAR T-cell expansion (supple-
mental Table 9; supplemental Figure 19).
Discussion
To elucidate factors that govern the clinical performance of CAR
T-cell therapy, we performed extensive analyses of prespecified
covariates and biospecimens collected during the ZUMA-1
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T cells commensurate with TB is critical to achieving durable response after axi-cel. (A-F) Logistic
regression analysis of response (right) and durable response (middle) and quartile analysis of peak CAR T-cell levels and peak CAR T-cell levels normalized to TB
(left) by the number of CD8 T cells (A-C) or the number of CD8 T cells normalized to TB (D-F). (G) The number of CD8 T cells among patients with low TB (below
median, left) and high TB (above median, right) by response. (H-P) Logistic regression analysis of response (right), durable response (middle), and quartile analysis
of peak CAR T-cell levels and peak CAR T-cell levels normalized to TB (left) by the number of CCR71CD45RA1 T cells (H-J), the number of CCR71CD45RA1
T cells normalized to TB (K-M), or CD4:CD8 ratio (N-P). P values were calculated using Kruskal-Wallis and Dunn’s tests for box plots. Spearman’s correlation was
used to calculate R and P values for bar graphs.
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routine lymphoma prognostic markers, were not predictive for
clinical outcomes. The most significant determining factors for
durable response were in vivo CAR T-cell expansion commen-
surate with pretreatment TB and influenced by intrinsic product
T-cell fitness, dose of specialized T-cell subsets, and host systemic
inflammation.
Suboptimal product T-cell fitness was a major factor related to
primary treatment resistance, and limited numbers of CCR71
CD45RA1 or CD8 T cells in proportion to TB were associated
with a failure to achieve durable response. Although numbers of
CD4 T cells did not significantly associate with durable
response, these results do not preclude the overall importance
of CD4 T cells in CAR T-cell therapy because a specialized
subset of polyfunctional CD4 T cells has been identified that
correlates with clinical response.22 In addition, high TB, pro-
nounced inflammatory status (reflected by myeloid activation
markers before and after CAR T-cell infusion), and excess type 1
cytokines associated negatively with durable efficacy and positively
with severe toxicities.
In this study, the strongest correlate of durable response was
peak CAR T-cell levels in blood normalized to pretreatment TB.
This index was positively associated with durable response rate,
and it separated subsets of patients with high (;60%) vs low
(;10%) probability of achieving a durable response. Our data
also highlight the value of estimating number of CAR cells per
unit of blood volume, because in our study, it was a more
informative pharmacokinetic measurement compared with the
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Figure 6. Factors differentially associated with toxicities: TB, inflammatory markers, and key product attributes. Logistic regression analysis of the probability of
grade $3 NE (left) or CRS (right) and baseline TB (A), the number of peak CAR T-cells normalized to TB (B), the number of CCR71CD45RA1 CD8 T cells normalized to TB
(C), baseline IL-6 (D), day 1 ferritin (E), day 1 CCL2 (F), baseline LDH (G), and IFN-g (H). P values were calculated using logistic regression.
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typically reported in other studies, and also reported here.
Ongoing efforts to harmonize reporting methods are warranted.
The number of CAR T cells in peripheral blood early (within 2
weeks) after infusion were associated with clinical efficacy.
However, CAR levels at later points were not significantly
associated with durable efficacy, concordant with another
recent report with a different CAR product in the same tumor
type.36 We previously demonstrated that most responders show
profound tumor regression at the first assessment (28 days),
that levels of the immune effector molecule granzyme B peak
within 5 days postinfusion,28 and that normal B cells recover
gradually in durable responders.6 Our results here, taken
together with previous findings, suggest that the window for
axi-cel anti-tumor activity in LBCL likely occurs within the first
weeks after infusion. These findings are consistent with the
hypothesis that axi-cel may act rapidly against LBCL tumors,
through early activation and expansion of CAR T cells with
2 weeks after treatment and driven by CCR71CD45RA1 T cells
in the product infusion bag; persisting CAR T cells are not
needed to achieve and maintain durable clinical response.6,7,31
Higher numbers of CAR T cells in the peripheral blood were
associated with DT, which underscores the importance of intrinsic
T-cell fitness independent of the CAR construct. Diminished
product T-cell fitness (ie, high DT) was associated with primary
treatment resistance because most nonresponding patients
showed a product DT .1.6 days. We demonstrate that the
higher the frequency of CCR71CD45RA1 T cells in the product
infusion bag, the higher the product T-cell fitness, because the
frequency of CCR71CD45RA1 T cells was negatively associated
with DT. Recently, we reported that the majority of CCR71CD45RA1
T cells in the axi-cel product infusion bag are stem-like memory cells,
not canonical naı̈ve T cells.37 This aligns with our observation that the
subpopulation that best associated with DT was CCR71CD45RA1
CD271CD281 T cells, noting that such specialized T-cell subsets
have been previously described and linked with product T-cell
performance.38-41 Our findings also corroborate with preclinical
data pointing to CCR71CD45RA1 cells as drivers of anti-tumor
activity in the context of T-cell intervention.42,43 That CCR71
CD45RA1 T cells from peripheral blood can differentiate in vitro
into stem-like memory cells, both of which express CCR7 and
CD45RA,43,44 provides a biological link for our observations that
CCR71CD45RA1 T cells in both the apheresis material and the
product associate with DT and outcomes.43 Furthermore, we
demonstrated that rather than the total number of product T cells
or CAR T cells, it was the total number of specialized T cells
normalized to pretreatment TB that associated best with clinical
efficacy. In addition, the frequency of CCR71CD45RA– T cells in
the product infusion bag associated inversely with DT, a result
that is concordant with the view that this subset may drive T-cell
product performance.45
Besides product attributes linked to T-cell fitness and dose of
specialized T cells, we also found that markers related to TB and
inflammation, both of which may be influenced by the underlying
tumor biology, were highly associated with clinical outcomes.
Pretreatment serum levels of LDH and proinflammatory markers,
including IL-6 and ferritin, were prominently and negatively
associated with clinical efficacy and were positively but weakly
associated with TB. Concordantly, patients with low TB and
diminished tissue hypoxia and inflammation markers demon-
strated a high durable response rate (.60%) and limited rate of
inflammation-driven serious adverse events (CRS and neuro-
toxicity; ,10%). Evidence of excessive activation and mobiliza-
tion of myeloid cells in the context of CAR T-cell therapy has also
been generated in preclinical models.46-48 Our univariable and
multivariable analyses of patient data indicate that tumor hypoxia
and an enhanced proinflammatory state reminiscent of myeloid
cell hyperactivity might inhibit the activation, expansion, and/or
survival of CAR T cells within the tumor microenvironment, while
simultaneously contributing to toxicities, possibly through facilitating
excess cytokine production.
On the basis of these findings, we suggest several strategies for
increasing efficacy without exacerbating the toxicity profile of axi-
cel: (1) systematic evaluation of bridging therapy agents (which
were not allowed in ZUMA-1) to curb TB and inflammation before
CAR T-cell infusion; (2) testing of agents that modulate effects
on myeloid cells or low-dose corticosteroids administered
immediately before or after CAR T-cell infusion; (3) optimization
of CAR configuration to eliminate excess production of myeloid
and type 1 molecules by the product cells; (4) dosing or process
optimizations to increase both the percentage and number of
product CCR71CD45RA1 and CD8 T cells, especially in the
context of bulky disease; and (5) improving T-cell fitness through
optimizing product T-cell metabolism or combining with immune
checkpoint modulators.
This study builds extensively on earlier findings with key product
attributes and patient and tumor characteristics.6,8,9,19,49 To our
knowledge, this represents the most extensive covariate analysis of
its kind: several variables were examined on a relatively large uniform
patient population treated with a specific CAR T-cell therapy with
extended follow-up. Although previously published reports were
limited in terms of total number of patients, breadth of categories of
covariates analyzed, and clinical follow-up, they also pointed to CAR
T-cell expansion and associated factors as major determinants of
clinical efficacy for this therapeutic modality in lymphoma.8,9,49 A
recent report with a different CAR product in LBCL similarly
assessed associations between CAR kinetics, durable response,
and toxicities.36 Our study expands upon those findings with a more
detailed product and biomarker analysis and a larger proportion of
durable responders, and for the first time, it reports associations
between product T-cell fitness, phenotypes, dose of specialized
T cells, and clinical outcomes. We propose that achieving durable
response requires CAR T-cell expansion within each patient that is
commensurate with that patient’s TB, and that to achieve this is
specifically attributable to the frequency of CCR71CD45RA1
Figure 7. TB, LDH, and pro-inflammatory markers measured before CAR T-cell infusion associate differentially with clinical outcomes in multivariable
analysis. (A) Cluster analysis summarizing the strength of association between covariates from the 2 major categories: product attributes and pretreatment tumor/inflammatory
markers. (B-D) Top covariates differentially associated with efficacy and NEs (B), efficacy and CRS (C), and NEs and CRS (D) by random forest analysis (n 5 97-101 patients
per parameter [supplemental Table 9]). (E) Summary of multivariable findings. CRP, C-reactive protein.
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CD81 CAR T cells in the product infusion bag. Insufficient expansion
in proportion to TB may allow for minimal residual malignancy above
or below levels of detection and may lead to a partial response or an
apparent complete response before relapse as a result of tumor
outgrowth. Another mechanism of transient remission is ascribable to
CD19-related evasion through selection of tumor cells that lack the
axi-cel target, and ongoing studies indicate that this may occur in
about 25% to 33% of the treated patients who have an objective
response. This hypothesis also aligns with our observation that
patient-related characteristics and product characteristics associate
differentially with response and toxicities.
When interpreting these results, several study limitations must be
considered: (1) this analysis did not characterize other potential
mechanisms of treatment resistance under evaluation, such as
tumor immune microenvironment–mediated suppression,50-52 es-
cape with target-negative variants,53 or product immunogenicity54;
(2) patients in ZUMA-1 may not entirely represent patients treated
with standard-of-care axi-cel because of differences in eligibility
criteria and toxicity management55; (3) the multivariable evaluation
used here was deliberately limited in scope, using random forest
analysis primarily directed at validating and comparing the impact of
the biological covariates identified in univariable analysis; (4) the
study was not designed to evaluate adverse event management
strategies because treatment guidelines evolved throughout the
course of ZUMA-1, adverse event management was ultimately at
the discretion of the physician, and ZUMA-1 did not assess the
impact of concomitant medications, which are often administered
before the first measurement of CAR T-cell expansion described
here; (5) NEs in ZUMA-1 were graded according to Common
Terminology Criteria for Adverse Events version 4, but a consensus
grading system for neurotoxicity was recently developed56 that may
complicate extrapolating these data to future patients; and (6)
because of the time-consuming nature of the extensive biomarker
analyses, follow-up was limited to 1 year after CAR T-cell therapy for
all patients, although we anticipate that later clinical follow-up would
provide consistent results with those presented here, given the
durability of responses between 1 and 2 years and that no patients
had new CRS or NEs.6
Future studies should evaluate the impact of these categories of
factors in broader patient populations and tumor types. Novel
approaches, including product optimization and combination
strategies, should be prospectively tested in clinical trials aimed at
safely improving durable remissions.
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